ArticleScientific reports2025
Construction and validation of antibody dependent cell phagocytosis related risk model in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-dependent cellular phagocytosis (ADCP) has potential in breast cancer (BRCA) treatment, but the prognostic significance of ADCP-associated regulators (PRs) in BRCA remains unclear, necessitating this study. Firstly, candidate genes were identified by crossing differentially expressed genes (DEGs) with PRs, and prognostic genes were selected from these. A risk model based on SIAH2 and PIGR was constructed and validated in the GSE42568 cohort. We also assessed the relationship between expression of prognostic genes and clinical characteristics. From these, independent prognostic factors were selected and a nomogram was constructed to predict survival in BRCA patients. Immune microenvironment analysis revealed that PIGR had the strongest positive correlation with naive B cells, while SIAH2 showed the strongest negative correlation with activated memory CD4 T cells. Moreover, drug sensitivity analysis revealed that 109 drugs differed between high- and low-risk groups. Meanwhile, single-cell analysis identified epithelial cells (EPCs) as key cells, with PIGR highly expressed in the middle stage and SIAH2 in the early stage of cell differentiation. Finally, reverse transcription quantitative polymerase chain reaction (RT-qPCR) confirmed the up-regulation of SIAH2 and down-regulation of PIGR in BRCA. These findings suggest that SIAH2 and PIGR are potential prognostic genes and novel therapeutic targets for BRCA management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.